ATA Guidelines Tools

Thyroid Disease in Preconception, Pregnancy, and Postpartum

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1545288

Contents of this Issue

Navigation

Page 35 of 53

Hyperthyroidism 36 Figure 5. Strategy for ATD Discontinuation Upon Pregnancy Confirmation a For MMI/CMZ, the teratogenic period ends at approximately 16 weeks for skin defects, while the risks for other congenital anomalies remain elevated generally throughout the first trimester. b e 1 year risk of Graves' disease relapse typically ranges between 30–70% following ATD discontinuation based on risk factors in the text. Conception Week 5 Week 10 Week 20 Birth TSH Receptor Abs and/or TSI Graves' hyperthyroidism relapse risk b STOP PTU/MMI

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Thyroid Disease in Preconception, Pregnancy, and Postpartum